keyword
MENU ▼
Read by QxMD icon Read
search

Tamoxifen aromatase

keyword
https://www.readbyqxmd.com/read/29135127/is-switching-to-tamoxifen-the-only-choice-of-treatment-for-improving-aromatase-inhibitor-toxicity
#1
Kadri Altundag
No abstract text is available yet for this article.
September 2017: Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology
https://www.readbyqxmd.com/read/29131988/treatment-adoption-and-relative-effectiveness-of-aromatase-inhibitors-compared-to-tamoxifen-in-early-breast-cancer-a-multi-institutional-observational-study
#2
Arlindo R Ferreira, Ana Palha, Lurdes Correia, Pedro Filipe, Vasco Rodrigues, Ana Miranda, Rosário André, João Fernandes, Joaquim Gouveia, José L Passos-Coelho, António Moreira, Margarida Brito, Joana Ribeiro, Otto Metzger-Filho, Nancy U Lin, Luís Costa, Inês Vaz-Luis
BACKGROUND: Since 2005, aromatase inhibitors (AIs) have been the adjuvant treatment of choice for postmenopausal women with early breast cancer (BC). In this study we characterize the adoption of AIs in Portugal, variables associated with treatment administration, and compare its effectiveness (either in monotherapy or sequential therapy) to tamoxifen monotherapy (TAM). PATIENTS AND METHODS: This was a retrospective cohort study that included postmenopausal women with stage I-III hormone receptor (HR) positive BC diagnosed from 2006 to 2008 and treated with adjuvant endocrine therapy in four participating institutions...
November 10, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/29103853/adherence-to-adjuvant-endocrine-therapy-in-christchurch-women-with-early-breast-cancer
#3
B Robinson, B Dijkstra, V Davey, S Tomlinson, C Frampton
AIMS: To assess adherence to adjuvant endocrine therapy by a real-world cohort of women in Christchurch and to determine any associated factors. MATERIALS AND METHODS: Records were retrieved of all women newly diagnosed with early breast cancer and registered on the Christchurch Breast Cancer Patient Register over 4 years from June 2009. Demographic and pathological factors, dates of starting and stopping endocrine therapies and reported side-effects were collected...
November 2, 2017: Clinical Oncology: a Journal of the Royal College of Radiologists
https://www.readbyqxmd.com/read/29100043/treatment-landscape-of-advanced-breast-cancer-patients-with-hormone-receptor-positive-her2-negative-tumors-data-from-the-german-praegnant-breast-cancer-registry
#4
Andreas D Hartkopf, Jens Huober, Bernhard Volz, Naiba Nabieva, Florin-Andrei Taran, Judith Schwitulla, Friedrich Overkamp, Hans-Christian Kolberg, Peyman Hadji, Hans Tesch, Lothar Häberle, Johannes Ettl, Michael P Lux, Diana Lüftner, Markus Wallwiener, Volkmar Müller, Matthias W Beckmann, Erik Belleville, Pauline Wimberger, Carsten Hielscher, Matthias Geberth, Nikos Fersis, Wolfgang Abenhardt, Christian Kurbacher, Rachel Wuerstlein, Christoph Thomssen, Michael Untch, Peter A Fasching, Wolfgang Janni, Tanja N Fehm, Diethelm Wallwiener, Sara Y Brucker, Andreas Schneeweiss
PURPOSE: This study describes comprehensive data from a breast cancer registry concerning the use of endocrine treatment (ET) and chemotherapy in the first, second and higher therapy lines in hormone receptor (HR) positive, HER2 negative metastatic breast cancer (MBC). METHODS: The PRAEGNANT study is a real-time registry for patients with MBC. Therapies were categorized into the following categories: chemotherapy, aromatase inhibitor (AI), tamoxifen, fulvestrant, or everolimus plus ET and reported for first, second and third line or higher therapy use...
October 26, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/29098396/survival-benefit-of-tamoxifen-and-aromatase-inhibitor-in-male-and-female-breast-cancer
#5
Holm Eggemann, Udo Altmann, Serban-Dan Costa, Atanas Ignatov
BACKGROUND: Our goal was to compare the survival advantage of tamoxifen (TAM) and aromatase inhibitor (AI) in female (FBC) and male breast cancer (MBC). PATIENTS AND METHODS: We performed a retrospective study of 2785 FBC and 257 MBC patients treated with hormonal therapy. RESULTS: The median follow-up was 106 months (range 3-151 months) and 42 months (range 2-115 months) for FBC and MBC, respectively. The patients were divided into two groups according to the hormonal therapy used: TAM-treated and AI-treated...
November 2, 2017: Journal of Cancer Research and Clinical Oncology
https://www.readbyqxmd.com/read/29071118/influence-of-aromatase-inhibitors-therapy-on-the-occurrence-of-rheumatoid-arthritis-in-women-with-breast-cancer-results-from-a-large-population-based-study-of-the-italian-society-for-rheumatology
#6
Marta Caprioli, Greta Carrara, Garifallia Sakellariou, Ettore Silvagni, Carlo Alberto Scirè
OBJECTIVES: The purpose of this study was to evaluate the risk of developing rheumatoid arthritis (RA) in a population of patients with breast cancer treated with aromatase inhibitors (AIs) compared with tamoxifen. METHODS: Data were collected from the administrative healthcare database of Lombardy Region, Italy, from 2004 to 2013. This study follows a nested cohort design, including women with a diagnosis of breast cancer starting treatment with tamoxifen, anastrozole, exemestane or letrozole...
2017: RMD Open
https://www.readbyqxmd.com/read/29066307/aromatase-inhibitors-are-associated-with-low-sexual-desire-causing-distress-and-fecal-incontinence-in-women-an-observational-study
#7
Penelope J Robinson, Robin J Bell, Marie K Christakis, Stephanie R Ivezic, Susan R Davis
BACKGROUND: Little is known of the impact of aromatase inhibitor (AI) therapy on sexual and pelvic floor function. AIM: To document the prevalence of, and factors associated with, low desire, sexually related personal distress, hypoactive sexual desire dysfunction (HSDD), and pelvic floor dysfunction in women 10 years after breast cancer diagnosis. METHODS: This was a prospective, observational, community-based cohort study of Australian women with invasive breast cancer recruited within 12 months of diagnosis...
October 21, 2017: Journal of Sexual Medicine
https://www.readbyqxmd.com/read/29061559/a-survey-among-breast-cancer-specialists-on-the-low-uptake-of-therapeutic-prevention-with-tamoxifen-or-raloxifene
#8
Silvia Noonan, Ambra Pasa, Vincenzo Fontana, Silvia Caviglia, Bernardo Bonanni, Alberto Costa, Samuel G Smith, Fedro Peccatori, Andrea DeCensi
With this survey, we aimed to address the reasons why physicians are reluctant to prescribe breast cancer preventive therapy with the selective oestrogens receptor modulators (SERMs) tamoxifen or raloxifene despite a strong evidence of efficacy. A self-administered 5-point Likert questionnaire was given during breast cancer meetings in Europe or sent via email to rank the importance of 10 pre-defined reasons for low uptake of SERMs for breast cancer therapeutic prevention. Analyses tested the associations between the stated reasons and physician characteristics such as gender, age, country of work and specialty...
October 23, 2017: Cancer Prevention Research
https://www.readbyqxmd.com/read/29056966/endocrine-therapy-initiation-among-older-women-with-ductal-carcinoma-in-situ
#9
Chelsea Anderson, Aaron N Winn, Stacie B Dusetzina, Hazel B Nichols
BACKGROUND: Although treatment of ductal carcinoma in situ (DCIS) is controversial, national guidelines recommend considering endocrine therapy for women with estrogen receptor- (ER-) positive DCIS or those undergoing breast conserving surgery (BCS) without radiation. We evaluated uptake and predictors of endocrine therapy use among older women with DCIS. METHODS: In the SEER-Medicare database, we identified women aged 65+ years diagnosed with DCIS during 2007-2011...
2017: Journal of Cancer Epidemiology
https://www.readbyqxmd.com/read/29031778/extended-adjuvant-aromatase-inhibition-after-sequential-endocrine-therapy-data-a-randomised-phase-3-trial
#10
Vivianne C G Tjan-Heijnen, Irene E G van Hellemond, Petronella G M Peer, Astrid C P Swinkels, Carolien H Smorenburg, Maurice J C van der Sangen, Judith R Kroep, Hiltje De Graaf, Aafke H Honkoop, Frans L G Erdkamp, Franchette W P J van den Berkmortel, Maaike de Boer, Wilfred K de Roos, Sabine C Linn, Alexander L T Imholz, Caroline M Seynaeve
BACKGROUND: The effect of extended adjuvant aromatase inhibition in hormone receptor-positive breast cancer after sequential endocrine therapy of tamoxifen followed by an aromatase inhibitor for a 5-year treatment period still needs clarification. To address this issue, we began the DATA study to assess different durations of anastrozole therapy after tamoxifen. METHODS: DATA was a prospective, randomised, open-label, multicentre, phase 3 study done in 79 hospitals in the Netherlands...
October 11, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28992264/proteasome-26s-subunit-psmd1-regulates-breast-cancer-cell-growth-through-p53-protein-degradation
#11
Toshiyuki Okumura, Kazuhiro Ikeda, Takafumi Ujihira, Koji Okamoto, Kuniko Horie-Inoue, Satoru Takeda, Satoshi Inoue
Endocrine therapy using antiestrogens and aromatase inhibitors is usually efficient to treat patients with hormone-sensitive breast cancer. Many patients with endocrine therapy, however, often acquire resistance. In the present study, we performed functional screening using short hairpin RNA library to dissect genes involved in antiestrogen tamoxifen resistance in MCF-7 breast cancer cells. We identified seven candidate genes that are associated with poor prognosis of breast cancer patients based on clinical dataset...
August 3, 2017: Journal of Biochemistry
https://www.readbyqxmd.com/read/28973704/neoadjuvant-and-adjuvant-therapies-for-breast-cancer
#12
REVIEW
Susmitha Apuri
Breast cancer remains the most common cancer in women in the United States, the second most common cause of cancer death, and the main cause of death in women ages 45 to 55 years. Molecular analyses have shown that breast cancer is divided into several subtypes (luminal A, luminal B, human epidermal growth factor receptor 2 [HER2] enriched, and basal-like), based on microarray techniques. Patients diagnosed as having breast cancer may undergo adjuvant or neoadjuvant chemotherapy, depending on the tumor size, hormone receptor, HER2/neu status, and desire for breast preservation...
October 2017: Southern Medical Journal
https://www.readbyqxmd.com/read/28969348/grip-strength-in-women-being-treated-for-breast-cancer-and-receiving-adjuvant-endocrine-therapy-systematic-review
#13
REVIEW
E M Van der Weijden-Van Doornik, Dagmar E Slot, Chris Burtin, G A van der Weijden
Background: Adjuvant endocrine therapy in breast cancer has increased survival rates; however, it is not without musculoskeletal side effects. Purpose: The purpose of this review was to systematically and critically appraise the available scientific evidence concerning the effect of adjuvant endocrine treatment on grip strength in women being treated for breast cancer. Data sources and study selection: The National Library of Medicine (MEDLINE-PubMed), Cochrane Central Register of Controlled Trials (CENTRAL), Excerpta Medical Database by Elsevier (EMBASE), Cumulative Index to Nursing and Allied Health Literature (CINAHL), and Physiotherapy Evidence Database (PEDro) were searched from inception to February 2017 for appropriate papers that could answer the focused question...
September 1, 2017: Physical Therapy
https://www.readbyqxmd.com/read/28948418/obesity-and-survival-in-the-neoadjuvant-breast-cancer-setting-role-of-tumor-subtype-in-an-ethnically-diverse-population
#14
Ying L Liu, Anurag Saraf, Benjamin Catanese, Shing M Lee, Yuan Zhang, Eileen P Connolly, Kevin Kalinsky
BACKGROUND: Obesity may negatively affect survival in breast cancer (BC), but studies are conflicting, and associations may vary by tumor subtypes and race/ethnicity groups. METHODS: In a retrospective review, we identified 273 women with invasive BC administered Adriamycin/Taxane-based neoadjuvant chemotherapy from 2004 to 2016 with body mass index (BMI) data at diagnosis. Obesity was defined as BMI ≥30. Associations between obesity and event-free survival (EFS), using STEEP events, and overall survival (OS), using all-cause mortality, were assessed overall and stratified by tumor subtype [[Hormone Receptor Positive (HR+)/HER2-, HER2+, and Triple-Negative Breast Cancer (TNBC])] in our diverse population...
September 25, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28937963/ki67-and-lymphocytes-in-the-pretherapeutic-core-biopsy-of-primary-invasive-breast-cancer-positive-markers-of-therapy-response-prediction-and-superior-survival
#15
REVIEW
Claus M Schlotter, Lothar Tietze, Ulf Vogt, Carlos Villena Heinsen, Antje Hahn
Background Core needle biopsy plays a crucial role as diagnostic tool for BC. Both Ki67 and likely tumor-infiltrating lymphocytes (TILs) in the near future are determining the kind of systemic therapy. The role of TILs in BC is still an issue for clinical research, albeit preliminary results of neoadjuvant and adjuvant clinical studies already now highlight the crucial impact of TILs on therapy response and survival. Methods Evaluation of related publications (pubmed) and meeting abstracts (ASCO, SABCS). Results The monoclonal antibody Ki67 recognizing a nuclear antigene in proliferating cells is a positive marker of therapy response and superior survival...
September 22, 2017: Hormone Molecular Biology and Clinical Investigation
https://www.readbyqxmd.com/read/28933369/epigenetic-mechanisms-of-tamoxifen-resistance-in-luminal-breast-cancer
#16
REVIEW
Hany A Abdel-Hafiz
Breast cancer is one of the most common cancers and the second leading cause of cancer death in the United States. Estrogen receptor (ER)-positive cancer is the most frequent subtype representing more than 70% of breast cancers. These tumors respond to endocrine therapy targeting the ER pathway including selective ER modulators (SERMs), selective ER downregulators (SERDs) and aromatase inhibitors (AIs). However, resistance to endocrine therapy associated with disease progression remains a significant therapeutic challenge...
July 6, 2017: Diseases (Basel)
https://www.readbyqxmd.com/read/28894848/risk-reduction-strategies-in-breast-cancer-prevention
#17
REVIEW
Mauricio Costa, Paula Saldanha
Evaluating the risk of breast cancer makes it possible to identify women with a high risk of developing breast cancer in the future. Adopting a healthier lifestyle, involving diet and exercise, is one way of reducing this risk-but there are other, non-modifiable risk factors, such as family history, genetics and diagnosis of premalignant lesions. In this high-risk population, the tracking must be rigorous and involve the participation of the patient herself, earlier and more frequent clinical assessment, and the use of imaging screening...
July 2017: Eur J Breast Health
https://www.readbyqxmd.com/read/28884392/socioeconomic-status-and-breast-cancer-treatment
#18
REVIEW
Marie S Dreyer, Ann B Nattinger, Emily L McGinley, Liliana E Pezzin
PURPOSE: Evidence suggests substantial disparities in breast cancer survival by socioeconomic status (SES). We examine the extent to which receipt of newer, less invasive, or more effective treatments-a plausible source of disparities in survival-varies by SES among elderly women with early-stage breast cancer. METHODS: Multivariate regression analyses applied to 11,368 women (age 66-90 years) identified from SEER-Medicare as having invasive breast cancer diagnosed in 2006-2009...
September 7, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28862123/results-of-1-year-diet-and-exercise-interventions-for-er-pr%C3%A2-her2-breast-cancer-patients-correlated-with-treatment-type
#19
Diana V Artene, Cristian I Bordea, Alexandru Blidaru
PURPOSE: Many breast cancer patients gain weight during chemotherapy and antiestrogenic treatment increasing recurrence, oncologic specific and all-cause mortality risks. Patients and Methods: 165 ER+/PR±/HER2- breast cancer patients under antiestrogenic treatment were randomly assigned to follow an at-home diet based on food naturally high in proteins, calcium, probiotics and prebiotics (D), or this diet and 4' isometric exercises (D+Ex) for 1 year. We measured weight (W), body (BF) and visceral fat (VF) using a multi-frequency bioelectrical impedance scale on the 6th and 12th month and we correlated results with chemotherapy, surgery and antiestrogenic medication type...
July 2017: Chirurgia
https://www.readbyqxmd.com/read/28862117/hormone-therapy-in-breast-cancer
#20
Mădălina Drăgănescu, Codruţa Carmocan
Hormonal therapy is mandatory for all patients with hormonereceptor- positive breast neoplasms. It is active both in adjuvant and metastatic disease. The only active adjuvant hormonal therapy in pre- and postmenopause is Tamoxifen. The adjuvant treatment duration influences disease-free survival, the risk of a contralateral breast cancer apparition and overall survival. The aromatase inhibitors: Anastrozol, Letrozol, Exemestan are only used in postmenopause. Fulvestrant is used in recurrent disease after or during treatment with Tamoxifen...
July 2017: Chirurgia
keyword
keyword
30009
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"